Bennett CL - Search Results

1

Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.

Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL. Adams JR, et al. Among authors: bennett cl. Am J Med. 2004 Jan 1;116(1):28-34. doi: 10.1016/j.amjmed.2003.06.004. Am J Med. 2004. PMID: 14706663

2

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. Smith TJ, et al. Among authors: bennett cl. J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682719

3

Reassessments of ESAs for cancer treatment in the US and Europe.

Bennett CL, McKoy JM, Henke M, Silver SM, MacDougall IC, Birgegård G, Luminari S, Casadevall N, Schellekens H, Sartor O, Lai SY, Armitage JO. Bennett CL, et al. Oncology (Williston Park). 2010 Mar;24(3):260-8. Oncology (Williston Park). 2010. PMID: 20394138 Free article.

4

G-CSF as prophylaxis of febrile neutropenia in SCLC.

Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL. Adams JR, et al. Among authors: bennett cl. Expert Opin Pharmacother. 2002 Sep;3(9):1273-81. doi: 10.1517/14656566.3.9.1273. Expert Opin Pharmacother. 2002. PMID: 12186620 Review.

5

Clinical trials: are they a good buy?

Bennett CL, Adams JR, Knox KS, Kelahan AM, Silver SM, Bailes JS. Bennett CL, et al. J Clin Oncol. 2001 Dec 1;19(23):4330-9. doi: 10.1200/JCO.2001.19.23.4330. J Clin Oncol. 2001. PMID: 11731516

6

Erythropoietin, uncertainty principle and cancer related anaemia.

Clark O, Adams JR, Bennett CL, Djulbegovic B. Clark O, et al. Among authors: bennett cl. BMC Cancer. 2002 Sep 24;2:23. doi: 10.1186/1471-2407-2-23. BMC Cancer. 2002. PMID: 12270068 Free PMC article.

7

Pharmacoeconomics of therapy for ITP: steroids, i.v.Ig, anti-D, and splenectomy.

Adams JR, Nathan DP, Bennett CL. Adams JR, et al. Among authors: bennett cl. Blood Rev. 2002 Mar;16(1):65-7. doi: 10.1054/blre.2001.0186. Blood Rev. 2002. PMID: 11913999 Review.

8

Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.

Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, Anderson JR. Bennett CL, et al. J Clin Oncol. 1995 Apr;13(4):969-73. doi: 10.1200/JCO.1995.13.4.969. J Clin Oncol. 1995. PMID: 7707125

9

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Adams JR, Angelotta C, Bennett CL. Adams JR, et al. Among authors: bennett cl. J Clin Oncol. 2006 Jul 1;24(19):2975-7. doi: 10.1200/JCO.2006.05.6812. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682722 No abstract available.

10

Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Bennett CL, et al. Arch Intern Med. 2010 Sep 13;170(16):1490-8. doi: 10.1001/archinternmed.2010.309. Arch Intern Med. 2010. PMID: 20837837 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

679 results

Search Page